This relatively large study by Meng et al. (Obstetrics Gynecology, 2017) aimed to determine if pregnancy outcomes vary by cause and severity of pulmonary hypertension, mode of delivery and whether modern therapies affect outcomes.
Retrospective Cohort Study
Even with advanced intensive care and therapies, mortality was still high among the 49 women surveyed, at 16%, and all deaths occurred postpartum. Not surprisingly, mortality was higher in the severe pulmonary hypertension group (mean pulmonary artery pressure ≥ 50 mm Hg or systolic pulmonary artery pressure ≥ 70 mm Hg) at 18% (4/22), compared to 5% (1/19) among women with mild pulmonary hypertension (mean pulmonary artery pressure 25-49 mm Hg). C-sections mortality rate was 18% (4/22) compared to 5% for vaginal delivery (1/19). Neuraxial anesthesia was performed in 20/22 C-sections and 17/19 vaginal births without incident. Women suffering from severe pulmonary hypertension required more advanced therapies, such as inotropes, pulmonary vasodilators, and extracorporeal membrane oxygenation, than those with mild pulmonary hypertension (73% vs. 31.8%). Women with severe pulmonary hypertension had almost double the rates of preterm delivery compared to the group with mild pulmonary hypertension (82.6% vs. 47.1%) with no neonatal deaths reported. The authors suggest that in a carefully selected subset of women with pulmonary hypertension, vaginal delivery should be considered.
Pulmonary Hypertension in Pregnancy: A Report of 49 Cases at Four Tertiary North American Sites
Pulmonary hypertension and pregnancy: The experience of a tertiary institution over 15 years
Please log in to access OBGFirst and the 2T Ultrasound Atlas
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
